Vicencio, Jeremy http://orcid.org/0000-0002-7291-3365
Sánchez-Bolaños, Carlos
Moreno-Sánchez, Ismael http://orcid.org/0000-0001-5606-4028
Brena, David
Vejnar, Charles E. http://orcid.org/0000-0002-7132-4534
Kukhtar, Dmytro
Ruiz-López, Miguel
Cots-Ponjoan, Mariona
Rubio, Alejandro
Melero, Natalia Rodrigo
Crespo-Cuadrado, Jesús
Carolis, Carlo http://orcid.org/0000-0003-4240-1139
Pérez-Pulido, Antonio J. http://orcid.org/0000-0003-3343-2822
Giráldez, Antonio J. http://orcid.org/0000-0002-6823-137X
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Cerón, Julián http://orcid.org/0000-0003-4739-2243
Moreno-Mateos, Miguel A. http://orcid.org/0000-0001-5723-0569
Article History
Received: 31 May 2021
Accepted: 22 April 2022
First Online: 12 May 2022
Competing interests
: The authors declare the following competing interests: B.P.K. is an inventor listed on U.S. Provisional Patent applications filed my Mass General Brigham that describe the development of the SpG and SpRY variants, including application 17/157,708 entitled “Unconstrained Genome Targeting With Near-PAMless Engineered CRISPR-Cas9 Variants” and application 17/157,805 entitled “CRISPR-Cas Enzymes With Enhanced On-Target Activity. B.P.K. is a consultant for Avectas Inc., EcoR1 capital, and ElevateBio, and is an advisor to Acrigen Biosciences, Life Edit Therapeutics and Prime Medicines. All the other authors declare no competing interests.